SCHEMBL3277604

SCHEMBL3277604

N=C(N)Nc1ccc(-c2cccc(O)c2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 8/20 0.59
HSD17B2 P37059 7/20 0.59
CYP3A4 P08684 2/20 0.59
CYP2C9 P11712 2/20 0.59
CNR1 P21554 1/20 0.48
ESR1 P03372 4/20 0.46
ESR2 Q92731 3/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2B6 P20813 1/20 0.46
CYP2C19 P33261 1/20 0.46
KDM1A O60341 2/20 0.45
HDAC6 Q9UBN7 1/20 0.45
KIF11 P52732 1/20 0.44
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
ABL1 P00519 1/20 0.43
ABCB1 P08183 1/20 0.43
BCR P11274 1/20 0.43
HPGDS O60760 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27114725 0.83 MAOA (0.52) CYP3A4CNR1KIF11
SCHEMBL27846380 0.81 WDR5 (0.54) KMT2AMEN1
SCHEMBL399197 0.81 KIF11 (0.48) KIF11
SCHEMBL1593329 0.80 KMT2A (0.66) CYP3A4CYP1A2HDAC6KMT2AMEN1
Hydrochloric Acid SCHEMBL1591965 0.78 KMT2A (0.63) CYP3A4CYP1A2HDAC6KMT2AMEN1
SCHEMBL4681786 0.78 KIF11 (0.43) CNR1KIF11KMT2AMEN1
SCHEMBL4681791 0.78 TRIM24 (0.53) CNR1KIF11
SCHEMBL7898375 0.77 HSD17B1 (1.00) HSD17B1HSD17B2CYP3A4CYP2C9ESR1
SCHEMBL25277661 0.77 MGLL (0.61) CNR1HDAC6
Hydrochloric Acid SCHEMBL2543304 0.77 KMT2A (0.61) CYP3A4CYP1A2HDAC6KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7700605-B2 2-cyano-pyrimidines and-triazines as cysteine protease inhibitors NOVARTIS AG (CH) 2010-04-20 US disclosed
US-20080214548-A1 2-Cyano-Pyrimidines and-Triazines as Cysteine Protease Inhibitors FLOHR STEFANIE 2008-09-04 US disclosed
EP-1907368-A1 2-CYANO-PYRIMIDINES AND -TRIAZINES AS CYSTEINE PROTEASE INHIBITORS Novartis AG (CH) 2008-04-09 EP disclosed
WO-2007009715-A1 2-CYANO-PYRIMIDINES AND -TRIAZINES AS CYSTEINE PROTEASE INHIBITORS NOVARTIS AG (CH) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214548-A1 2-Cyano-Pyrimidines and-Triazines as Cysteine Protease Inhibitors USP2, UCHL3, UCHL5 HSD17B1 3684/4885HSD17B2 3104/4885CYP3A4 2908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.